Terms: = Cervical cancer AND MUC16, CA125, CA-125 AND Clinical Outcome
7 results:
1. Immunophenotype and human papillomavirus status of serous adenocarcinoma of the uterine cervix.
Togami S; Sasajima Y; Kasamatsu T; Oda-Otomo R; Okada S; Ishikawa M; Ikeda S; Kato T; Tsuda H
Pathol Oncol Res; 2015 Apr; 21(2):487-94. PubMed ID: 25370301
[TBL] [Abstract] [Full Text] [Related]
2. [Tumor makrers in cervical cancer].
Markowska J
Ginekol Pol; 2007 Sep; 78(9):715-8. PubMed ID: 18159826
[TBL] [Abstract] [Full Text] [Related]
3. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer: a review of the literature.
Gadducci A; Tana R; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2008 Apr; 66(1):10-20. PubMed ID: 17964182
[TBL] [Abstract] [Full Text] [Related]
4. Biochemical prognostic factors and risk of relapses in patients with cervical cancer.
Gadducci A; Tana R; Fanucchi A; Genazzani AR
Gynecol Oncol; 2007 Oct; 107(1 Suppl 1):S23-6. PubMed ID: 17727924
[TBL] [Abstract] [Full Text] [Related]
5. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract] [Full Text] [Related]
6. Pelvic inflammatory disease. Correlation of severity with ca-125 levels.
Moley KH; Massad LS; Mutch DG
J Reprod Med; 1996 May; 41(5):341-6. PubMed ID: 8725760
[TBL] [Abstract] [Full Text] [Related]
7. Multiple tumour marker assays in advanced cervical cancer: relationship to chemotherapy response and clinical outcome.
Scambia G; Benedetti Panici ; Foti E; Ferrandina G; Leone FP; Marciano M; Mancuso S
Eur J Cancer; 1996 Feb; 32A(2):259-63. PubMed ID: 8664038
[TBL] [Abstract] [Full Text] [Related]
